Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

NCT07349693 is registered in ClinicalTrials.gov with Everfront Biotech Co., Ltd. as lead sponsor.

NCT NCT07349693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07349693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial to Assess the Efficacy and Safety of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Lead sponsor
Everfront Biotech Co., Ltd.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
April 1, 2027
Completion date
December 31, 2029
Enrollment
175 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma, idh-wildtype